Pharma — India Trademark Cases
454 decisions indexed
Page 12 of 16 · 454 total
Sun Pharma Laboratories Limited v.Psycoremedies Ltd.
The civil suit was filed regarding the alleged infringement of a trademark. The parties subsequently entered into a Memo of Compromise, resolving all disputes between them.
S.K.Janimiya (M/s.Crescent Therapeutics Ltd.) v.Mr.Narender Pal; Deputy Registrar of Trade Marks; Intellectual Property Appellate Board
The Madras High Court allowed the writ petition filed by S.K.Janimiya challenging an adverse order from the Intellectual Property Appellate Board (IPAB) regarding the trademark OLAPIN. While noting the petitioner's lackadaisical conduct and delay in presenting evidence, the court ultimately set aside the IPAB's finding that no documents were filed. The matter was remitted back to the IPAB for a fresh examination, allowing them to consider the records and take further evidence.
Pfizer Products, Inc & Anr v.Platinum Pharmaceuticals Pvt Ltd & Ors
The Delhi High Court ruled in favor of Pfizer Products, Inc. in a suit alleging trademark infringement and passing off by Platinum Pharmaceuticals Pvt Ltd. The court found that the defendant was illegally selling a drug under the deceptively similar trademark BEQSULE against the plaintiff's registered mark BECOSULES. Furthermore, the court noted that the defendant adopted an identical trade dress (white and reddish orange color combination) to mislead consumers, leading to a decree of injunction.
Sanofi-Aventis Deutschland GmbH v.Jagdale Industries Private Limited
Sanofi-Aventis challenged the registration of Jagdale Industries' trademark 'CALDALE,' arguing that it was deceptively similar to their own mark 'CARDACE.' The Madras High Court examined the phonetic similarity and potential for consumer confusion, especially given that both products are prescription medicines. Ultimately, the court found no remote possibility or slightest chance of confusion, dismissing Sanofi-Aventis' appeal and upholding the trademark registration.
Sanofi Aventis v.Intas Pharmaceuticals Ltd.
Sanofi Aventis filed a suit against Intas Pharmaceuticals Ltd. alleging trademark infringement and passing off related to blood thinning medicines. The plaintiff sought permission to amend the plaint to reflect significantly increased damages, as the losses mounted over the seven years the suit was pending. The court allowed the amendment, emphasizing that procedural rules should not obstruct the cause of justice, especially when correcting valuation based on evolving market realities.
Cadila Healthcare Limited v.Micro Labs Limited
The Gujarat High Court addressed an appeal concerning a suit filed under Section 142 of the Trademark Act. While addressing procedural matters, the court granted ad-interim relief in favor of the appellant (Cadila Healthcare Limited). This interim order mandates that the respondent (Micro Labs Limited) must provide at least one week's prior written notice before initiating any legal proceedings related to the dispute against the appellant.
M/S Relianc Life Sciences Pvt Ltd v.M/S Reliance Life Sciences & Anr
This Delhi High Court order confirms the settlement reached between M/S Relianc Life Sciences Pvt Ltd and M/S Reliance Life Sciences & Anr. The parties successfully mediated their dispute, leading to a decree that acknowledges the plaintiff's proprietary trademark rights. While the plaintiff agreed to waive damages, the defendants formally acknowledged the validity of the plaintiff's trademarks, resolving the litigation amicably.
Bestochem Formulations(I) Limited v.Mr.Nitin Blaggan & Ors.
In a significant resolution, Bestochem Formulations(I) Limited successfully concluded its dispute against Mr. Nitin Blaggan & Ors. by reaching an amicable out-of-court settlement. The Delhi High Court decreed the suit based on this agreement, which confirmed that Bestochem is the rightful owner of the trademark 'FLUWEL' for pharmaceutical preparations. In exchange for this confirmation, the plaintiff agreed to forgo claims for damages and costs, bringing a long-pending infringement case to a definitive close.
Parul Homoeo Laboratory Pvt. Ltd. v.Royal Group
Parul Homoeo Laboratory Pvt. Ltd. filed a suit for permanent injunction and passing off against Royal Group regarding the use of similar trade marks ('HAEMOFORTE' vs 'HAEMO FORTE') in pharmaceutical preparations. The plaintiff claimed prior user rights, but the defendant challenged the court's territorial jurisdiction, arguing that its operations were based outside Delhi. The Court ultimately found that since neither party had a presence or cause of action arising within Delhi, it lacked the necessary jurisdiction to proceed with the suit.
Medical Technologies Limited v.M/S Neon Laboratories Limited
The Gujarat High Court addressed Letters Patent Appeals concerning interim orders related to a trademark registration dispute. While not delving into the merits of the infringement claim, the court granted the appellant (Medical Technologies Limited) liberty to approach the Single Judge to seek an early hearing and suitable modification of the existing interim orders. This decision allowed the parties to pursue their claims without being unduly influenced by the appellate ruling.
Blue Cross Laboratories Ltd. v.RB Remedies Pvt. Ltd. & Anr.
The Bombay High Court ruled in favor of Blue Cross Laboratories, granting an interim injunction against RB Remedies Pvt. Ltd. The court found that the marks 'CEDON' and 'CEFDON' were deceptively similar, establishing a prima facie case for trademark infringement and passing off. Furthermore, the court allowed the plaintiff to combine both causes of action into the suit, dismissing the defendant's attempt to reject the plaint.
Sun Pharmadeuticals Industries Ltd. v.Stadmed Pvt. Ltd. & Anr.
The Calcutta High Court allowed an application for amendment of the cause title, recognizing that the rights in the trademark 'ZOLAM' had been transferred from Sun Pharmadeuticals Industries Ltd. to Sun Pharma Laboratories Limited via a sanctioned scheme of arrangement. The court found the plaintiff's case unimpeachable and ruled that the successor company was entitled to continue the legal proceedings without delay.
Neon Laboratories Ltd. v.Themis Medicare Ltd. and Ciron Drugs & Pharmaceuticals Pvt. Ltd.
The Bombay High Court granted interim relief in favor of Neon Laboratories Ltd. against Themis Medicare Ltd. and Ciron Drugs & Pharmaceuticals Pvt. Ltd., finding a prima facie case of trademark infringement and passing off. The court held that the Defendants' use of the 'XYLOX Family' marks was deceptively similar to the Plaintiff's established 'LOX Family' marks, despite the addition of the prefix 'XY'. Consequently, the Court issued an injunction restraining the Defendants from using the rival marks and ordered the appointment of a Court Receiver over the infringing goods.
Sun Pharmaceuticals Industries Ltd v.Midley Pharmaceuticals Limied
This Calcutta High Court case involves a passing-off dispute between Sun Pharmaceuticals and Midley Pharmaceuticals concerning the trademarks CARDIVAS and CARVAS. The court framed ten detailed issues, focusing on whether the plaintiff is the proprietor of CARDIVAS, whether the defendant's mark CARVAS is confusingly similar or an imitation, and ultimately, whether the defendant is engaging in passing off. The case was fixed for settlement of these complex trademark infringement claims.
Baroda Pharma Pvt. Ltd. v.Torrent Pharmaceuticals Ltd.
The Gujarat High Court addressed an appeal challenging a lower court's decision to dismiss a notice of motion seeking perpetual injunction against trademark infringement. The suit involved the trademarks 'VAL' and 'VALZ'. The High Court upheld the trial judge’s finding that there was no sufficient basis for immediate injunctive relief, noting differences in pronunciation, structure, and packaging between the two marks. Furthermore, the court emphasized the limited scope of appellate review over discretionary interim orders, directing the trial court to expedite the final hearing on merits.
Dolphin Laboratories P. Ltd. v.Deputy Registrar Of Trademark
The Calcutta High Court addressed an appeal filed by Dolphin Laboratories P. Ltd. against the Deputy Registrar of Trademark. The petitioner argued that the appeal should be transferred to the Intellectual Property Appellate Board (IPAB) due to amendments made to the Trade Mark Act, 1999. Consequently, the court recorded the disposal of TMA No. 2195 of 1995.
G.M.Bell Health Care Pvt.Ltd v.Universal Skin Impex Pvt Ltd
The Gujarat High Court upheld the trial court's decision granting an interim injunction in favor of G.M.Bell Health Care Pvt.Ltd against Universal Skin Impex Pvt Ltd. The dispute centered on the use of product names and trademarks for various medicines, where the appellant claimed ownership via a 2005 assignment deed. The court found no illegality in the trial court's order, allowing the plaintiff to continue restraining infringement while noting that the final decision remains subject to pending litigation before the Bombay High Court.
Mr Pramod Hegde (M/S Meditek India) v.M/S Indchemie Health Specialities Pvt. Ltd.
The Karnataka High Court dismissed a writ petition challenging the Intellectual Property Appellate Board's decision to deny trademark registration. The dispute centered on whether 'Z-CAL' (Petitioner) was deceptively similar to 'ZECAL' (Respondent). Applying established tests for deceptive similarity, the court found that despite minor spelling differences, the marks were phonetically and visually similar, especially within the pharmaceutical industry where buyers rely heavily on pronunciation. Consequently, the court upheld the prior user's rights, preventing the registration of the petitioner's mark.
M/S. Mankind Pharma Ltd. v.M/S. Mascot Drugs Pvt. Ltd.
Mankind Pharma Ltd. filed a suit against Mascot Drugs Pvt. Ltd. alleging infringement and passing off concerning their registered trademarks OMIDON and EMEDOM in pharmaceutical preparations. The plaintiff claimed that the defendant was using the deceptively similar mark 'OMEDO' to confuse consumers and erode goodwill. The court found in favor of the plaintiff, granting an injunction and damages.
Sun Pharmaceuticals Industries Ltd. v.Mukesh Kumar P. & Ors.
The Delhi High Court ruled in favor of Sun Pharmaceuticals Industries Ltd. (SPIL) against the defendants, finding that their use of the mark AMLOVATE constituted both trademark infringement and passing off against SPIL's registered mark, AMLOBET. The court affirmed SPIL's territorial jurisdiction despite the defendants' objections. Consequently, the suit was decreed with a permanent injunction and an order requiring the defendants to render accounts of profits.
Orchid Chemicals & Pharmaceuticals Ltd. v.Wockhardt Limited
Orchid Chemicals & Pharmaceuticals Ltd. appealed against the dismissal of its interim injunction application, alleging that Wockhardt Limited was infringing their registered trademark "METO" with "METOX". The court dismissed the appeal, holding that the appellant could not maintain the suit because the required assignment deed procedure under the Trade Marks Act, 1999, had not been completed.
Unimed Technologies Ltd. v.M/s Eyekare Kilitch Ltd.
The Madras High Court dismissed Original Side Appeals filed by Unimed Technologies Ltd. and Sun Pharmaceutical Industries Limited against a prior order dismissing their injunction application. The court found that the mark 'TOBA', being derived from the generic chemical term Tobramycin, was publici juris. Furthermore, the court noted factual dissimilarities in color schemes and symbols between the products, concluding there was no prima facie case of passing off or consumer confusion, especially since both drugs are sold under prescription by specialized physicians.
Macleods Pharmaceuticals Ltd. v.Procare Laboratories Pvt. Ltd.
The Delhi High Court ruled in favor of Macleods Pharmaceuticals, finding that Procare Laboratories was engaging in passing off by using the name 'Procare' as part of its corporate identity. The court emphasized that for a passing-off action, trademark registration is not essential; rather, prior use and established goodwill are key. Given the defendant's deliberate absence from court proceedings, the court also awarded punitive damages to deter dishonest conduct.
United Biotech Pvt. Ltd. v.Orchid Chemicals & Pharmaceuticals Ltd
The Delhi High Court dismissed the appeal filed by United Biotech Pvt. Ltd., upholding the Intellectual Property Appellate Board's decision to remove its trademark FORZID from the register. The court found that the respondent, Orchid Chemicals & Pharmaceuticals Ltd, had successfully demonstrated a likelihood of confusion between their earlier registered mark ORZID and the appellant's mark FORZID in the pharmaceutical sector. This judgment reinforces the principle that even sophisticated buyers can be misled by deceptively similar marks operating in the same field.
Astrazeneca Uk Ltd & Ors v.Orchid Chemicals & Pharmaceuticals Ltd.
The Delhi High Court dismissed an application filed by Orchid Chemicals seeking a stay of infringement proceedings against Astrazeneca. The court held that since Astrazeneca had previously challenged the validity of Orchid’s mark, Orchid was barred from filing rectification proceedings without first obtaining prima-facie satisfaction from the Court. The judgment emphasized judicial discipline and the principle of estoppel, preventing parties from taking contradictory pleas on the same issue.
Merck Kgaa v.Galaxy Hompro And Anr
The Delhi High Court dismissed Merck Kgaa's appeal against the Intellectual Property Appellate Board (IPAB) decision, upholding the registration of the trademark 'RECIBION'. The court found no deceptive similarity between 'CEBION' and 'RECIBION', emphasizing that the common suffix 'BION' is widely used in the pharmaceutical industry. Crucially, the judgment noted the petitioner's lack of recent use of its mark and applied the strict test for confusion, concluding that the marks were sufficiently distinct.
Sun Pharmaceuticals Industries Limited v.Emcure Pharmaceuticals Limited
The Bombay High Court addressed a suit concerning trademark infringement and passing off between Sun Pharmaceuticals (owner of 'SUSTEN') and Emcure Pharmaceuticals (owner of 'SUSTINEX'). Although the plaintiff was the prior user, the court ultimately found that 'SUSTINEX' was not deceptively similar to 'SUSTEN'. The judgment emphasized phonetic distinctiveness, noting a clear audible divide in 'SUSTINEX', leading to the dismissal of the plaintiff's notice of motion.
Ranbaxy Laboratories Limited v.M/S Intas Pharmaceuticals Ltd.
The Delhi High Court addressed a passing off suit filed by Ranbaxy Laboratories against Intas Pharmaceuticals regarding the alleged similarity between their drug trademarks, 'NIFTRAN' and 'NIFTAS'. While the plaintiff sought an interim injunction, the court did not grant a blanket injunction. Instead, it directed the defendant to maintain complete accounts of sales and profits from the product sold under 'NIFTAS', and imposed specific restrictions on packaging types used by the defendant pending further proceedings.
The Himalaya Drug Company & Ors. v.Surjit Singh Sial & Anr.
The Delhi High Court ruled in favor of The Himalaya Drug Company, granting a permanent injunction against the defendant's website for trademark infringement, passing off, and copyright violation. The court found that the defendants were unauthorizedly selling and promoting Himalaya products while creating a false impression of being authorized dealers. Furthermore, the parties settled on damages, with the defendants agreeing to pay Rs. 30,000/- to the plaintiffs.
Pfizer Products Inc. v.B.P.Singh Tyagi
Pfizer successfully sued B.P.Singh Tyagi and his company for trademark infringement and passing off related to their cough syrup product. The Delhi High Court found that the defendant's mark, OREX, was phonetically and deceptively similar to Pfizer's registered mark, COREX. Consequently, the court granted a permanent injunction restraining the defendant from using the infringing mark and awarded punitive damages.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.